Year-end Sale % OFF 
Abstract
Background: In this updated analysis using a recent pooled clinical trial population, we examined the incremental burden of comorbid psoriatic arthritis (PsA) on the clinical efficacy and safety of secukinumab vs ustekinumab among patients with moderate to severe plaque psoriasis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
